Targeted anti-inflammatory therapies, including colchicine, TNF inhibitors, IL-6 inhibitors, and IL-1 blockers, have demonstrated cardiovascular protective effects in select populations [139], but their long-term safety and efficacy in CID patients require further investigation. This evidence concerns the gene IL6 and combined immunodeficiency.